Pharming Group N.V.

NASDAQ:PHAR

Biotechnology

Healthcare
$12.48 +2.19%

+$0.28 today

Market cap
$882.43M
Beta
0.10
P/E (TTM)
77.0
EPS (TTM)
$0.02
52W Low $9.54High $21.34

Volume 0.01M

Average 0.01M

PHAR Income Before Tax

Profit after all operating and non-operating items but before income tax.

Pharming Group N.V.NASDAQ: PHAR

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$4.75M, compared with -$11.79M a year earlier. Trailing-twelve-month income before tax was $19.88M. Over 3 fiscal years it compounded at -4.9% a year.

Context

  • Income before tax amounted to 3.4% of revenue in FY2025, up 0.6 pp from a year earlier.
  • Income before tax increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$4.75M or moves back toward the trailing-twelve-month quarterly average of $4.97M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.75M-199.1% QoQ
Last fiscal yearDec 2025
$12.88M+246.5% YoY
LTMMar 2026
$19.88M+643.8% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+59.7%——
1 year+246.5%——
3-year CAGR-4.9%——
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
12.88M USD
Year-over-year change
+246.5%
4-year CAGR
-16.2%

Income Before Tax vs competitors

How PHAR compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +643.8% is the highest of 9, against a peer median of -80.1%.
  • Income before tax amounts to 5.4% of revenue for PHAR, versus a peer median of 339.3%.
PHAR Competitors
Income Before Tax for PHAR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PHARPharming Group N.V.LTM Mar 2026$19.88M USD+643.8%-4.9%5.4%
PRQRProQR Therapeutics N.V.LTM Mar 2026-€45.61M EUR-50.1%—339.3%
SLNSilence Therapeutics plcLTM Mar 2026-$85.16M USD——9241.5%
STOKStoke Therapeutics, Inc.LTM Mar 2026-$171.05M USD-431.8%—533.2%
PHVSPharvaris N.V.LTM Sep 2026-€179.08M EUR-8.9%——
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026-$209.38M USD+18.9%——
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026-$381.19M USD-1084.0%—40.5%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-$394.6M USD+25.0%—597.0%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-$543.8M USD-110.2%—56.7%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-$131.59B USD-19472.7%+47.8%12.8%
Peer median (excluding PHAR) —-80.1%+47.8%339.3%

Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue225.46M205.62M245.32M307.75M377.18M
Cost of Revenue23.97M17.56M25.21M36.66M45.63M
Gross Profit201.49M188.06M220.1M271.09M331.56M
Gross Margin89.4%91.5%89.7%88.1%87.9%
Research & Development79.78M52.53M68.91M86.1M98.08M
Selling, General & Admin54.56M68.85M87.5M102.74M117.44M
Operating Expenses186.12M169.83M225.49M280.02M309.75M
Depreciation & Amortization22.23M13.19M15.93M16.64M10.76M
EBITDA55.3M33.53M9.88M16.89M31.7M
EBITDA Margin24.5%16.3%4.0%5.5%8.4%
Operating Income15.37M18.23M(5.39M)(8.93M)20.88M
Operating Margin6.8%8.9%-2.2%-2.9%5.5%
Interest Income59.99K85K3.53M5.92M2.56M
Interest Expense7M5.36M5.96M9.05M21.31M
Other Income / Expenses10.79M(3.25M)(6.63M)133.58K(8.03M)
Income Before Tax26.16M14.99M(12.01M)(8.79M)12.88M
Pre-Tax Margin11.6%7.3%-4.9%-2.9%3.4%
Income Tax Expense8.03M1.31M(1.46M)3.47M10.34M
Net Income18.13M13.67M(10.55M)(12.26M)2.86M
Net Margin8.0%6.7%-4.3%-4.0%0.8%
EPS (Basic)0.230.17(0.14)(0.18)0.04
EPS (Diluted)0.210.16(0.14)(0.18)0.04
Weighted Avg Shares87.64M82.54M65.7M68.92M71.32M
Weighted Avg Shares (Diluted)87.64M84.28M65.7M68.92M71.32M

Pharming Group N.V.

NASDAQ:PHAR

Intrinsic Alpha fair value

Locked

Current Price

$12.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.